DiaMedica Therapeutics Inc. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/33f8596c-4a6a-4163-aeda-514eed22ae63/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-34.4M | 2025-01-01 – 2025-12-31 | evidence 0001437749-26-010342 |
| FY 2024 | $-26.7M | 2024-01-01 – 2024-12-31 | evidence 0001437749-25-008018 |
| FY 2023 | $-21.3M | 2023-01-01 – 2023-12-31 | evidence 0001437749-24-008522 |
| FY 2022 | $-14.0M | 2022-01-01 – 2022-12-31 | evidence 0001437749-23-008189 |
| FY 2021 | $-13.6M | 2021-01-01 – 2021-12-31 | evidence 0001437749-22-006163 |
| FY 2020 | $-12.7M | 2020-01-01 – 2020-12-31 | evidence 0001437749-21-005541 |
| FY 2019 | $-11.6M | 2019-01-01 – 2019-12-31 | evidence 0001437749-20-005906 |
| FY 2018 | $-6.8M | 2018-01-01 – 2018-12-31 | evidence 0001437749-19-005272 |
| FY 2017 | $-4.5M | 2017-01-01 – 2017-12-31 | evidence 0001437749-19-005272 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).